Tenet Healthcare Corporation research snapshot
THC AI stock analysis views Tenet Healthcare as a scaled hospital and ambulatory-care operator with strong free cash flow, falling share count, and a growing USPI ambulatory platform. The important offset is that Q1 2026 included $413 million of contract-termination revenue, leverage remains material, and healthcare reimbursement, labor, payer mix, and regulatory conditions can change the earnings picture quickly. At the July 11, 2026 cutoff, the latest available July 8 close was $206.26 and that price multiplied by 88 million shares produced market capitalization near $18.15 billion. The THC AI stock forecast is scenario-based, not a precise price prediction, and this page is informational research rather than investment advice.
Current price
$206.26
Market cap
$18.15 billion
AI score
76 / 100
Rating
Cash-generative healthcare operator, event-sensitive
Trend status
Above 50-day and 200-day moving averages, momentum extended
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Tenet earns revenue from acute and specialty hospitals, outpatient facilities, revenue-cycle services, and United Surgical Partners International ambulatory sites. Customers pay for local clinical capacity, physician relationships, and specialized care access. | High |
| Moat | Local hospital licenses, physician networks, regulated operating know-how, and ambulatory scale create barriers, but healthcare markets remain competitive and payer economics limit pricing freedom. | Medium-high |
| Management | CEO Saum Sutaria has prioritized higher-acuity care, ambulatory expansion, debt reduction, and buybacks. The key test is whether capital deployment preserves balance-sheet flexibility through the cycle. | Medium-high |
| Financial trend | Q1 2026 revenue was $5.368 billion, adjusted EBITDA was $1.162 billion, and adjusted free cash flow was $978 million. The quarter included a $413 million early-contract-conclusion revenue item. | High |
| Valuation | Using $19.23 TTM diluted EPS and $38.88 free cash flow per share, financial_rigor.py verified about 10.7x earnings and 5.3x free cash flow at $206.26. Those trailing figures include a period with material non-recurring items. | Medium |
| Technical trend | The July 2 technical snapshot placed THC above the 50-day and 200-day averages, but RSI near 74 and a price near $206 indicated an extended momentum setup rather than a low-risk entry. | Medium |
| Risk level | Risk is moderate to high because leverage, reimbursement policy, labor availability, litigation, payer mix, acquisition execution, and unusual contract items can all move earnings and the multiple. | High |
| AI confidence | High for filings, cash-flow math, and current technical references. Medium for future scenarios because payer behavior, regulation, and hospital demand cannot be forecast reliably. | High data confidence |
| Investment certainty | Medium certainty. The operating model and cash generation are tangible, while the amount of normalized earnings after contract effects and future capital needs remain central open questions. | Medium |
THC AI stock forecast
The THC AI stock forecast uses scenario ranges around the $206.26 July 8 close rather than a point target. A financial_rigor.py three-scenario model using $19.23 TTM diluted EPS produced mechanical three-year outputs near $409.40 in a bull case, $266.50 in a base case, and $131.90 in a bear case. The model is a sensitivity exercise, not a prediction, and it does not normalize for contract-related revenue or future capital allocation.
$267 to $409
More likely if same-facility volumes and acuity remain strong, USPI expands at attractive returns, reimbursement stays supportive, leverage falls, buybacks continue, and normalized EPS compounds near 15% with a mid-teens earnings multiple.
$206 to $267
More likely if ambulatory growth and hospital operations remain solid but reported growth moderates after contract-related benefits, and the market values THC near an 11x earnings multiple.
$132 to $206
More likely if payer mix worsens, reimbursement or labor costs pressure margins, volumes soften, debt reduction slows, or investors apply a lower multiple to lower normalized earnings.
THC AI technical analysis
THC AI technical analysis starts from the $206.26 July 8, 2026 close. Investing.com reported a July 2 50-day simple moving average near $188.52, a 200-day simple moving average near $176.54, RSI of 73.72, and ATR of 3.10. Because this static page does not fetch request-time chart data, confirm live levels before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $206.26 | StockAnalysis listed this regular-session close on July 8, 2026. The July 11 cutoff follows the latest available close. |
| Near support | $188 to $190 | The July 2 50-day moving-average zone is the first broad trend support reference. |
| Near resistance | $206 to $210 | The latest close and the July 2 pivot area near $207 mark the first breakout zone. |
| 50-day moving average | About $188.52 | Investing.com snapshot dated July 2, 2026. Price was above this medium-term trend reference. |
| 200-day moving average | About $176.54 | Investing.com snapshot dated July 2, 2026. Price was above this long-term trend reference. |
| Momentum | Strong but extended | RSI was 73.72 and MACD was positive on July 2, indicating momentum but also an overbought risk. |
| Volume | Confirm on live chart | A breakout should be checked against current average volume because this static page does not carry a live volume feed. |
| Volatility | ATR about $3.10 | The July 2 ATR reference shows daily moves can be meaningful around earnings, reimbursement news, and hospital operating updates. |
| Invalidation | Sustained failure below $176 to $190 | A break below the 50-day area followed by failure around the 200-day average would weaken the trend-following setup. |
THC AI trading strategy
The THC AI trading strategy is a monitoring framework for a leveraged healthcare operator with strong recent momentum. It is not personalized advice and should be paired with position sizing, defined invalidation, earnings-date review, and current chart data.
Monitor for a hold above the $206 to $210 breakout area with current volume confirmation, while price remains above the $188 50-day reference. Recheck the thesis after quarterly results and payer-mix commentary.
Invalidate the setup if price loses the 50-day area on worsening fundamentals or if fresh results reveal weaker normalized cash flow after contract-related items.
If THC pulls back toward the $188 to $190 area, watch whether support holds while USPI growth, hospital volumes, free cash flow, and leverage progress remain intact.
Do not average down solely because the multiple looks low if reimbursement, labor, volume, or balance-sheet signals weaken.
Track same-facility revenue, admissions and surgeries, ambulatory adjusted EBITDA, payer mix, adjusted free cash flow, net debt to EBITDA, capital expenditures, acquisitions, and share repurchases.
Reduce confidence if per-share improvement relies mainly on buybacks while organic operating performance, leverage, or free cash flow deteriorate.
Investment research summary
Patients, physicians, employers, and payers pay Tenet for local hospital capacity, specialized acute care, ambulatory surgery access, and administrative healthcare services.
The moat is local and operational: hospital licenses, physician relationships, clinical capabilities, contracted payer networks, and the scale of USPI ambulatory sites. It is valuable but not immune to reimbursement and competitive pressure.
The failure path is mistaking a favorable earnings period for a permanent step-up: contract-related revenue fades, payer mix or labor costs turn, leverage constrains flexibility, and the market resets the earnings multiple.
Management has emphasized higher-acuity services, ambulatory care, disciplined operations, debt reduction, and repurchases. The capital-allocation question is whether acquisitions and buybacks earn more than a stronger balance sheet would.
An aging population, outpatient migration, and demand for specialized care support ambulatory growth, while reimbursement policy, staffing scarcity, consolidation, and payer negotiating power set the boundary conditions.
Trailing valuation screens low on earnings and free cash flow, but the margin of safety depends on normalizing contract-related revenue, maintaining cash conversion, and reducing leverage without impairing growth investment.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| THC price | $206.26 at the July 8 close | StockAnalysis quote snapshot | July 11, 2026 |
| Market capitalization | $18.15 billion, $206.26 times 88M shares | StockAnalysis quote and share-count snapshot | July 11, 2026 |
| FY2025 revenue | $21.31 billion | Tenet 2025 Form 10-K and StockAnalysis | July 11, 2026 |
| FY2025 income available to common shareholders | $1.407 billion | Tenet 2025 Form 10-K and StockAnalysis | July 11, 2026 |
| Q1 2026 net operating revenue | $5.368 billion, up from $5.223 billion | Tenet Q1 2026 results | July 11, 2026 |
| Q1 2026 adjusted EBITDA | $1.162 billion, 21.6% margin | Tenet Q1 2026 results | July 11, 2026 |
| Q1 2026 adjusted free cash flow | $978 million | Tenet Q1 2026 results | July 11, 2026 |
| Cash and total debt | $2.97 billion cash and $13.21 billion debt | StockAnalysis statistics snapshot | July 11, 2026 |
| Technical references | 50-day SMA $188.52, 200-day SMA $176.54, RSI 73.72 on July 2 | Investing.com technical snapshot | July 11, 2026 |
This THC AI stock analysis page is an informational tool only and is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 11, 2026 and can be wrong if fundamentals, valuation, technical trends, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
